Trial tests Tislelizumab plus Anlotinib as consolidation therapy in limited-stage SCLC
A new Phase II study is recruiting patients with limited-stage small cell lung cancer who did not progress after chemoradiotherapy.
This week's update covers one newly registered trial involving BeiGene's tislelizumab as a collaborator-supported study.
- A Phase II single-arm study is evaluating tislelizumab plus anlotinib as consolidation therapy in patients with limited-stage small cell lung cancer who have not progressed following concurrent or sequential chemoradiotherapy.1 The trial is sponsored by Yantai Yuhuangding Hospital, with BeiGene and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as collaborators. It is enrolling an estimated 20 participants1 and is currently recruiting, with a start date of November 4, 2025 and estimated primary completion by December 31, 2028. Primary outcomes include Progression Free Survival (PFS) and Overall Survival (OS).1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.